Treatment
Standard medical treatment clinical trials
We’re tracking 537 recruiting studies that include Standard medical treatment, each written for real people, not researchers, below.
Recruiting studies
- NCT05645107RecruitingPhase 3
XEMBIFY plus usual care to prevent infections
This Phase 3 study tests whether XEMBIFY (an immune protein therapy) plus standard medical treatment can better prevent serious or repeated infections. It is for people with certain cancers of blood/immune systems who are already having trouble with infections.
Bullhead City, ArizonaAges 18 years+ - NCT07195422Recruiting
Study of a new device for low back pain relief
This trial tests a wearable device called Japet.W+ to see if it can help reduce chronic low back pain. It might be an option for people who have had lower back pain for a long time and are looking for non-surgical relief.
Clermont-FerrandAges 18–80 - NCT07801638Recruiting
Anticoagulation plus tocilizumab for cerebral venous thrombosis
This trial tests a combination of blood thinners (anticoagulation) and a drug called tocilizumab, which targets inflammation, to treat acute cerebral venous thrombosis (a blood clot in a vein in the brain). It aims to see if this combined treatment improves recovery and reduces complications compared to blood thinners alone.
Beijing, Beijing MunicipalityAges 18–80 - NCT06621264Recruiting
Exercise study to improve walking in kidney and artery disease
This trial tests whether a supervised exercise program can help people with chronic kidney disease and peripheral artery disease walk better and feel stronger. It aims to improve mobility and quality of life.
Ferrara, ItalyAges 18–80 - NCT07347106Recruiting
Miro3D trial for hard-to-heal wounds
This trial tests a special dressing called Miro3D, used with or without a negative pressure wound therapy (NPWT) device, to help heal tough wounds that haven't improved with standard care. It may be an option for people with certain large surgical wounds or chronic pressure sores.
St Louis, MissouriAges 18–90 - NCT06788431RecruitingEarly Phase 1
Study of IMC-001 to stabilize heart artery plaque
This trial tests an investigational drug, IMC-001, to see if it can make artery plaques in the heart more stable and less likely to cause a heart attack. You may be eligible if you've recently had a heart attack or unstable angina and have a specific type of soft plaque in your arteries.
Nanyang, HenanAges 18–75 - NCT07043686Recruiting
Cerebrolysin for early stroke recovery
This trial tests if adding Cerebrolysin to standard rehabilitation helps people recover arm and hand function better after a first-time, moderate stroke. You may be eligible if you had a stroke and can follow simple instructions.
LjubljanaAges 18 years+ - NCT05733013Recruiting
Using redifferentiation medicines before radioactive iodine for thyroid cancer
This study collects information on how redifferentiation medicines used before radioactive iodine work in everyday care for certain thyroid cancers that are unlikely to respond to radioactive iodine. It may help doctors understand the best real-world way to use these medicines to plan and deliver treatment.
New York, New YorkAges 18 years+ - NCT07371247Enrolling by invitationEarly Phase 1
Adjuvant treatment guided by ctDNA after chemoradiation for esophageal cancer
This trial tests whether adjusting treatment based on a blood test (ctDNA) after standard chemoradiation can improve outcomes for patients with advanced esophageal squamous cell carcinoma. It aims to find a more personalized approach to prevent cancer recurrence.
Nanjing, JiangsuAges 18–80 - NCT07058376Enrolling by invitation
Herbal medicine for chronic low back pain
This trial tests whether a herbal medicine strategy can safely and effectively reduce chronic low back pain lasting over 3 months. It may be an option if your pain has been moderate to severe and you are looking for alternative treatments.
Seoul, Gangnam-GuAges 19–69 - NCT05374681Recruiting
Test a minimally invasive add-on treatment for brain vessel swelling
This trial studies whether an add-on, minimally invasive procedure works better than standard care for a specific brain blood-vessel problem (CSH) that is larger than 10 mm. It may help reduce symptoms or prevent worsening, if you meet the size and location requirements.
Amiens, FranceAges 18 years+ - NCT07021534RecruitingPhase 1
CAR-NK and CAR-T cells for cancer with liver spread
This trial tests a new treatment that uses special immune cells (CAR-NK and CAR-T cells) given directly into the liver artery, then through a vein, to fight advanced solid tumors that have spread to the liver. It is for people who have already tried standard treatments and need new options.
Hangzhou, ZhejiangAges 18–75 - NCT07357987RecruitingPhase 3
Stroke treatment with tenecteplase via artery
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
Beijing, Beijing MunicipalityAges 18 years+ - NCT03378934RecruitingPhase 4
Berberine after stent placement to reduce blood-platelet effects
This trial studies whether berberine changes how strongly your platelets “stick together” after a coronary stent. It may help reduce risk related to clotting while you continue standard heart medicines (aspirin and clopidogrel).
Beijing, Beijing MunicipalityAges 18–70 - NCT07079605Recruiting
Sepsis and heart inflammation study
This trial looks at how sepsis (a severe response to infection) affects the heart, specifically whether it causes inflammation of the heart muscle (myocarditis). It may help understand and improve care for people with sepsis.
Jimma, OromiyaAges 18 years+ - NCT07518901Enrolling by invitationPhase 4
New Nanoparticle Treatment for Root Canal Therapy
This study tests a new type of nanoparticle (tiny medical particles) called Ferumoxytol to help treat infected tooth roots. Researchers want to see if this approach works better than standard root canal treatments.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05700877RecruitingPhase 4
Screening and treatment for silent heart artery disease in type 2 diabetes
This trial tests a screening and intervention approach for “silent” coronary artery disease (heart artery narrowing without major symptoms) in people with type 2 diabetes. It may help prevent future heart problems by finding higher-risk cases early and starting the right treatment plan.
OdenseAges 55–75 - NCT06955169RecruitingPhase 2
Study of lutetium treatment for meningioma after prior therapy
This study tests a radioactive drug, lutetium-177 DOTATATE, against standard care for people whose meningioma has grown despite earlier surgery and radiation. The treatment targets a protein on tumor cells, which may slow or stop growth.
Irvine, CaliforniaAges 18 years+ - NCT04897516RecruitingPhase 3
Test whether shorter benznidazole courses work for Chagas
This trial compares a shorter course of benznidazole (a medicine for Chagas disease) to the standard longer treatment. It aims to see if the shorter regimen works as well and is safe for people with confirmed Chagas infection.
Buenos AiresAges 18–60 - NCT06193889RecruitingPhase 2/Phase 3
Car-t cell therapy for generalized myasthenia gravis
This trial tests a new cell therapy (CAR-T cells) for people with generalized myasthenia gravis. It aims to reduce symptoms and improve daily life by targeting and destroying faulty immune cells.
Los Angeles, CaliforniaAges 18–75 - NCT05577390Recruiting
Comparing two treatments for diabetic nerve pain
This study compares two approaches to treating nerve pain caused by diabetes. You may be eligible if your diabetic neuropathy is moderate to severe and you can reliably use a phone for study steps.
Loma Linda, CaliforniaAges 45–85 - NCT07503301Enrolling by invitation
Study on stroke recovery and limb therapy
This trial tests if a limb therapy called RIC can help people recover from a stroke caused by small vessel disease. It is designed for people aged 50-65 who have had a recent stroke and have few other health issues.
Hangzhou, ZhejiangAges 50–65 - NCT06645470Recruiting
Muscle and movement study for weight loss medications
This study looks at how anti-obesity medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) affect your muscles and movement. It may help researchers understand how to combine these drugs with exercise for better health.
Kansas City, KansasAges 18 years+ - NCT06781060Recruiting
Nerve stimulation for sciatic nerve injury in children
This trial tests if electrical nerve stimulation can help children aged 3 to 19 who have nerve damage in the leg caused by an injection. The goal is to improve nerve healing and leg function.
Multan, Punjab ProvinceAges 3–19
Common questions
- Are there clinical trials studying Standard medical treatment?
- Yes. Clin2 currently lists 537 recruiting studies that include Standard medical treatment, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Standard medical treatment trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Standard medical treatment an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Standard medical treatment or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.